CytoDyn (CYDY) is starting to attract some attention from all corners of the market, including some of the best champions of the bears. Notorious bear research firm, Citron Research, has been summoned to take on the seemingly unstoppable CYDY that has run-over previous challengers, including Adam Feuerstein. According to some accounts, Citron’s report pointed out that the stock’s recent run-up is not justified and the company has no data to claim that Leronlimab is a cure for COVID-19. Unfortunately, I cannot reference the report directly because the post was pulled shortly after posting